QIAGEN Beats Outlook for Fourth Quarter and Full-Year 2020, Reaffirms Expectations for Further Growth in 2021
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- US stock futures dip as oil breaches $100 mark for the first time since mid-year
- Oil nears $100 as fresh Middle East strikes raise supply risks
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Qiagen (QGEN) Tops Q4 EPS by 3c, Revenues Beat; Offers FY21 EPS Guidance Above Consensus
February 9, 2021 4:08 PM ESTQiagen (NYSE: QGEN) reported Q4 EPS of $0.68, $0.03 better than the analyst estimate of $0.65. Revenue for the quarter came in at $571.2 million versus the consensus estimate of $548.86 million.
Q4 2020 net sales rise 36% CER to $571.2 million, exceeding outlook of +32% CER, and adjusted diluted EPS grows 42% to $0.68 CER, exceeding outlook of ~$0.64-0.65 CERFull-year 2020 net sales increase 23% CER to $1.87 billion, exceeding outlook of ~+22% CER, and adjusted diluted EPS grows 52% to $2.17 CER, exceeding outlook of ~$2.13-2.14 CERFull-year 2020 operating cash flow rises 38% to $457.8 million, free cash flow grows 53%Continuously launching new COVID-19 solutions that also have non-COVID... More